The AREVA M5000 combines everything that makes a high quality offshore wind energy plant stand out: reliability, efficiency and high performance. Its technology is tried and tested and perfectly tailored to the conditions on the open sea. The M5000 is manufactured and certified according to the latest international standards (DIN ISO 9001 certificate).
Copy this code
The AREVA M5000 combines everything that makes a high quality offshore wind energy plant stand out: reliability, efficiency and high performance. Its technology is tried and tested and perfectly tailored to the conditions on the open sea. The M5000 is manufactured and certified according to the latest international standards (DIN ISO 9001 certificate).
7/4/2010 - 02:08 min
Global EPR™ Reactor deployment
Les Musicoliers (France): supporting sick children
"Bienvenue à la Business Unit mines" presentation [FR]
Future nuclear sites beyond service life - brochure
"AREVA HTR" marketing brochure
"AREVA at a glance" brochure
"Analyst day: Equipment BU" presentation
Game: Nuclear energy key words
Game: Energy Memory Game

The AREVA Foundation supports INSERM's research on premature infants.
Severely premature infants (i.e., babies born before 32 weeks of pregnancy) pose a serious public health problem.
These premature births are the leading cause of cerebral palsy and an important source of cognitive disabilities as well as behavioral and psychiatric problems that are often irreversible. These illnesses affect patients throughout their lives.
The UMR U676 research laboratory is the only INSERM research unit in France dedicated to the problem of cerebral illness in newborns, and premature infants in particular.
Among the research undertaken, studies focused on identifying the cellular and molecular mechanisms that contribute to lesion formation should enable better definition of new therapeutic targets.
To help with this research, the AREVA Foundation has provided funding to purchase a calcium imaging machine, which the laboratory now uses to perform the rapid and effective screening of molecules that are potentially neuroprotective for the brains of premature newborns. This is followed by clinical testing.
Before submitting your project, we encourage you to consult our strict criteria.